JP2023519246A5 - - Google Patents
Info
- Publication number
- JP2023519246A5 JP2023519246A5 JP2022557767A JP2022557767A JP2023519246A5 JP 2023519246 A5 JP2023519246 A5 JP 2023519246A5 JP 2022557767 A JP2022557767 A JP 2022557767A JP 2022557767 A JP2022557767 A JP 2022557767A JP 2023519246 A5 JP2023519246 A5 JP 2023519246A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai drug
- rnai
- sense strand
- drug according
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025168554A JP2026010008A (ja) | 2020-03-26 | 2025-10-06 | ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000137P | 2020-03-26 | 2020-03-26 | |
| US63/000,137 | 2020-03-26 | ||
| PCT/US2021/024299 WO2021195467A2 (en) | 2020-03-26 | 2021-03-26 | RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025168554A Division JP2026010008A (ja) | 2020-03-26 | 2025-10-06 | ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023519246A JP2023519246A (ja) | 2023-05-10 |
| JP2023519246A5 true JP2023519246A5 (https=) | 2024-04-03 |
| JP7830340B2 JP7830340B2 (ja) | 2026-03-16 |
Family
ID=75540055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557767A Active JP7830340B2 (ja) | 2020-03-26 | 2021-03-26 | ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法 |
| JP2025168554A Pending JP2026010008A (ja) | 2020-03-26 | 2025-10-06 | ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025168554A Pending JP2026010008A (ja) | 2020-03-26 | 2025-10-06 | ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12054718B2 (https=) |
| EP (1) | EP4125932A2 (https=) |
| JP (2) | JP7830340B2 (https=) |
| KR (1) | KR20220158011A (https=) |
| CN (2) | CN115397436B (https=) |
| AR (1) | AR121672A1 (https=) |
| AU (2) | AU2021242321B2 (https=) |
| BR (1) | BR112022019241A2 (https=) |
| CA (1) | CA3176418A1 (https=) |
| CL (2) | CL2022002580A1 (https=) |
| CO (1) | CO2022013746A2 (https=) |
| CR (1) | CR20220532A (https=) |
| DO (1) | DOP2022000204A (https=) |
| EC (1) | ECSP22075322A (https=) |
| IL (1) | IL296718A (https=) |
| JO (1) | JOP20220232A1 (https=) |
| MX (1) | MX2022011907A (https=) |
| PE (1) | PE20230345A1 (https=) |
| TW (1) | TW202202153A (https=) |
| UY (1) | UY39138A (https=) |
| WO (1) | WO2021195467A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201901841TA (en) * | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
| JP2020522510A (ja) | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| CA3065523A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| SG11202009877XA (en) | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| US12391942B2 (en) | 2018-05-11 | 2025-08-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| EP4347823A1 (en) * | 2021-06-02 | 2024-04-10 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| WO2023196941A1 (en) * | 2022-04-08 | 2023-10-12 | Arrowhead Pharmaceuticals, Inc. | Treatment of a non-alcoholic fatty liver disease |
| WO2025223315A1 (zh) * | 2024-04-25 | 2025-10-30 | 苏州时安生物技术有限公司 | 一种用于肝脏特异性递送的多靶标双链rna偶联物及药物组合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| DE60040274D1 (de) | 1999-03-10 | 2008-10-30 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| SI2539451T1 (sl) | 2010-02-24 | 2016-04-29 | Arrowhead Research Corporation | Sestavki za ciljano dostavo sirna |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| WO2013032829A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| CA2842041A1 (en) | 2012-04-18 | 2013-10-24 | Arrowhead Research Corporation | Poly(acrylate) polymers for in vivo nucleic acid delivery |
| CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| CA3011946A1 (en) | 2016-03-07 | 2017-09-14 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
| US10036024B2 (en) * | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
| SG11201901841TA (en) | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
| TN2020000038A1 (en) * | 2017-09-14 | 2021-10-04 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use |
| UY38003A (es) * | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
| EP4077666A1 (en) * | 2019-12-16 | 2022-10-26 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
-
2021
- 2021-03-26 AR ARP210100762A patent/AR121672A1/es unknown
- 2021-03-26 JP JP2022557767A patent/JP7830340B2/ja active Active
- 2021-03-26 BR BR112022019241A patent/BR112022019241A2/pt unknown
- 2021-03-26 WO PCT/US2021/024299 patent/WO2021195467A2/en not_active Ceased
- 2021-03-26 CN CN202180024737.5A patent/CN115397436B/zh active Active
- 2021-03-26 CN CN202510877568.XA patent/CN120699970A/zh active Pending
- 2021-03-26 US US17/213,787 patent/US12054718B2/en active Active
- 2021-03-26 TW TW110111184A patent/TW202202153A/zh unknown
- 2021-03-26 AU AU2021242321A patent/AU2021242321B2/en active Active
- 2021-03-26 CR CR20220532A patent/CR20220532A/es unknown
- 2021-03-26 UY UY0001039138A patent/UY39138A/es unknown
- 2021-03-26 KR KR1020227036413A patent/KR20220158011A/ko active Pending
- 2021-03-26 PE PE2022002098A patent/PE20230345A1/es unknown
- 2021-03-26 MX MX2022011907A patent/MX2022011907A/es unknown
- 2021-03-26 EP EP21719475.2A patent/EP4125932A2/en active Pending
- 2021-03-26 CA CA3176418A patent/CA3176418A1/en active Pending
- 2021-03-26 IL IL296718A patent/IL296718A/en unknown
-
2022
- 2022-09-23 DO DO2022000204A patent/DOP2022000204A/es unknown
- 2022-09-23 CL CL2022002580A patent/CL2022002580A1/es unknown
- 2022-09-25 JO JOJO/P/2022/0232A patent/JOP20220232A1/ar unknown
- 2022-09-26 EC ECSENADI202275322A patent/ECSP22075322A/es unknown
- 2022-09-26 CO CONC2022/0013746A patent/CO2022013746A2/es unknown
-
2023
- 2023-08-31 CL CL2023002586A patent/CL2023002586A1/es unknown
-
2024
- 2024-06-20 US US18/748,261 patent/US20250034577A1/en active Pending
-
2025
- 2025-10-06 JP JP2025168554A patent/JP2026010008A/ja active Pending
- 2025-11-11 AU AU2025267339A patent/AU2025267339A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519246A5 (https=) | ||
| JP2020533334A5 (https=) | ||
| CN113164509B (zh) | 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法 | |
| JP2022501040A5 (https=) | ||
| JP6924744B2 (ja) | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| TWI881004B (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| JP2023536974A5 (https=) | ||
| KR20200097751A (ko) | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 | |
| JP2020534268A5 (https=) | ||
| JP2020525011A (ja) | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 | |
| JP2018529732A5 (https=) | ||
| JP2019513384A5 (https=) | ||
| JP2023536999A (ja) | Ｂ型肝炎患者のオリゴヌクレオチド処置 | |
| US20240425859A1 (en) | Pharmaceutical combinations for treatment of hbv | |
| JP2022517742A5 (https=) | ||
| JP2024539193A5 (https=) | ||
| JP2024544532A5 (https=) | ||
| TW202120104A (zh) | 用於治療apoc3相關疾病及病症之方法 | |
| US20230123601A1 (en) | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv | |
| IL323704A (en) | Compounds and methods for reducing pln expression | |
| JP2023541170A (ja) | Ｚ－ａａｔタンパク質のレベルを低下させる方法 | |
| WO2021107143A1 (ja) | アンチセンス核酸の毒性を軽減する方法 | |
| HK40110728A (zh) | 用於治疗hbv的药物组合 | |
| CN121003688A (zh) | 一种dsRNA与干扰素的联合治疗 | |
| CN120829899A (zh) | 用于抑制NR1H3基因表达的RNAi剂及其制备方法和用途 |